meningioma (Cancer)
Information
- Disease name
- meningioma
- Disease ID
- DOID:3565
- Description
- "A central nervous system cancer that are manifested in the central nervous system and arise from the arachnoid cap cells of the arachnoid villi in the meninges." [url:http\://en.wikipedia.org/wiki/Meningioma]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| TP53 | 17 | 7,668,421 | 7,687,490 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04595786 | Active, not recruiting | N/A | The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection | October 30, 2020 | February 24, 2023 |
| NCT01117844 | Active, not recruiting | Phase 1/Phase 2 | Proton Radiation For Meningiomas and Hemangiopericytomas | February 4, 2010 | December 2024 |
| NCT03071874 | Active, not recruiting | Phase 2 | Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas | October 17, 2017 | July 25, 2024 |
| NCT02933736 | Active, not recruiting | Early Phase 1 | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | October 2016 | January 2025 |
| NCT01166321 | Active, not recruiting | N/A | Carbon Ion Radiotherapy for Atypical Meningiomas | June 2012 | February 2026 |
| NCT04478877 | Completed | Establishment and Characterization of Meningioma Patient-derived Organoids | May 23, 2020 | August 31, 2023 | |
| NCT02267928 | Completed | N/A | Information Presentation Formats | October 2014 | May 2016 |
| NCT02831257 | Completed | Phase 2 | AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas | August 31, 2016 | October 1, 2020 |
| NCT01347307 | Completed | N/A | Stereotactic Body Radiotherapy for Spine Tumors | September 2008 | September 2017 |
| NCT04305470 | Completed | Phase 3 | Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma | October 28, 2020 | December 13, 2022 |
| NCT01941602 | Completed | A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery | August 2013 | October 2015 | |
| NCT01967823 | Completed | Phase 2 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | October 24, 2013 | April 6, 2020 |
| NCT02162732 | Completed | N/A | Molecular-Guided Therapy for Childhood Cancer | July 8, 2014 | January 18, 2024 |
| NCT06180226 | Completed | Evaluation of Brain Functional Changes With 18F-FDG PET and Cognitive Processes After Brain Radiotherapy for Cavernous Sinus Meningiomas and Non-secreting ACTH Adenomas | April 21, 2008 | December 11, 2014 | |
| NCT03273712 | Completed | Phase 2 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | September 29, 2017 | May 27, 2020 |
| NCT03558516 | Completed | Phase 3 | Magnesium and Intraoperative Blood Loss in Meningioma Surgery | August 1, 2018 | February 18, 2020 |
| NCT00589784 | Completed | Phase 2 | Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma | October 2007 | October 2014 |
| NCT03648034 | Completed | N/A | Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality | September 18, 2018 | November 30, 2019 |
| NCT00706810 | Completed | Phase 2 | Combination of Hydroxyurea and Verapamil for Refractory Meningiomas | December 2007 | September 2015 |
| NCT03936426 | Completed | Phase 1/Phase 2 | Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™ | July 9, 2018 | September 19, 2019 |
| NCT03953131 | Completed | Phase 1 | Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas | January 10, 2019 | August 30, 2023 |
| NCT00859040 | Completed | Phase 2 | Monthly SOM230C for Recurrent or Progressive Meningioma | March 2009 | January 2016 |
| NCT04079595 | Completed | N/A | Closed vs. Open Face Masks for Cranial Radiotherapy | December 9, 2019 | May 31, 2022 |
| NCT04109404 | Completed | Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin | February 25, 2019 | June 1, 2019 | |
| NCT01811524 | Completed | The Etiology and Progression of Brain Tumors | September 1983 | March 2012 | |
| NCT05028400 | Completed | N/A | Intraoperative Laser Speckle Contrast Imaging to Assess Blood Flow During Neurosurgery | February 1, 2022 | March 11, 2022 |
| NCT05093751 | Completed | Automated Segmentation and Volumetry for Meningioma Using Deep Learning | March 23, 2013 | September 30, 2021 | |
| NCT03015701 | Completed | Phase 3 | S9005 Mifepristone in Meningioma | August 1992 | November 2012 |
| NCT06278103 | Enrolling by invitation | Correlation Between Expression of Hormonal Receptors, Clinical Data, and Methylation Profile in Meningiomas (MethylRH-M) | January 1, 2000 | September 1, 2024 | |
| NCT05821790 | Not yet recruiting | Role of the Tumor Microenvironment in Aggressive Meningiomas | May 2023 | May 2024 | |
| NCT05940493 | Not yet recruiting | Phase 2 | Abemaciclib in Newly Diagnosed Meningioma Patients | June 15, 2024 | December 2031 |
| NCT02978677 | Not yet recruiting | N/A | Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas | October 2022 | December 2029 |
| NCT06255249 | Not yet recruiting | Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide | July 30, 2024 | November 30, 2024 | |
| NCT04298541 | Not yet recruiting | Phase 2 | Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC | May 2024 | May 2025 |
| NCT06377371 | Not yet recruiting | Phase 4 | Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE | May 2024 | January 2025 |
| NCT06126588 | Not yet recruiting | Phase 2 | Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial | March 1, 2024 | May 1, 2028 |
| NCT06132685 | Not yet recruiting | Phase 2 | Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial | July 1, 2024 | July 30, 2028 |
| NCT06439420 | Not yet recruiting | Phase 2 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial | July 1, 2024 | November 30, 2026 |
| NCT06460467 | Not yet recruiting | Semi-automatic Segmentation Method for Determining 177Lu-DOTATATE Tumor Dosimetry | July 1, 2024 | July 1, 2024 | |
| NCT06012929 | Not yet recruiting | Phase 1 | A Study of ONC201 for Refractory Meningioma | April 2024 | April 2027 |
| NCT06036706 | Recruiting | N/A | Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: | September 13, 2023 | June 2039 |
| NCT02693990 | Recruiting | N/A | A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas | February 2016 | August 2027 |
| NCT03583528 | Recruiting | DOTATOC PET/CT for Imaging NET Patients | July 11, 2018 | December 31, 2028 | |
| NCT03702309 | Recruiting | Liquid Biopsy Evaluation and Repository Development at Princess Margaret | August 3, 2017 | July 6, 2024 | |
| NCT03971461 | Recruiting | Phase 2 | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | May 15, 2019 | May 2025 |
| NCT04081701 | Recruiting | Phase 4 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. | September 4, 2019 | December 31, 2038 |
| NCT04087902 | Recruiting | Long-Term Longitudinal QoL in Patients Undergoing EEA | July 16, 2019 | December 31, 2025 | |
| NCT04113395 | Recruiting | Concordance and Accuracy of MRI in the Detection of Meningiomas: Optimizing Sequences With Low Doses of Gadolinium | December 23, 2019 | December 2025 | |
| NCT04113408 | Recruiting | MEningioma Detection Using Non Contrast MRI TecHniquEs | June 12, 2020 | June 2027 | |
| NCT04189172 | Recruiting | MiDura-Study (Neuro-Patch in Duraplasty) | February 6, 2020 | January 2026 | |
| NCT04367779 | Recruiting | Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients. | September 24, 2020 | June 2024 | |
| NCT04372095 | Recruiting | Androcur® (Cyproterone Acetate) and Meningioma Development: a Genotype-environment Association Study | July 6, 2021 | April 19, 2025 | |
| NCT04374305 | Recruiting | Phase 2 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | June 20, 2020 | December 2030 |
| NCT04635657 | Recruiting | Cognitive Status After Removal of Skull Base Meningioma | December 10, 2019 | December 31, 2024 | |
| NCT04638478 | Recruiting | PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI | April 8, 2021 | April 8, 2025 | |
| NCT04648462 | Recruiting | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | January 1, 2018 | January 1, 2035 | |
| NCT04712214 | Recruiting | N/A | Use of Non-invasive Optical Analysis in Neurosurgery | March 28, 2021 | October 30, 2023 |
| NCT04997317 | Recruiting | Early Phase 1 | Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide | April 21, 2021 | December 31, 2025 |
| NCT05139277 | Recruiting | N/A | Evaluation of the CONVIVO System | June 28, 2022 | June 2025 |
| NCT05230381 | Recruiting | N/A | Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection | June 15, 2022 | June 30, 2025 |
| NCT05254197 | Recruiting | SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON) | January 1, 2001 | December 31, 2035 | |
| NCT05278208 | Recruiting | Phase 1/Phase 2 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | November 21, 2022 | November 2027 |
| NCT05416567 | Recruiting | N/A | Embolization for Meningioma | October 10, 2022 | August 2037 |
| NCT05425004 | Recruiting | Phase 2 | Cabozantinib for Patients With Recurrent or Progressive Meningioma | May 27, 2022 | May 2028 |
| NCT05576103 | Recruiting | Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients | January 2015 | December 2026 | |
| NCT05727605 | Recruiting | N/A | Neurocognition After Radiotherapy in CNS- and Skull-base Tumors | February 8, 2023 | February 1, 2027 |
| NCT05793034 | Recruiting | N/A | Predictive Factors for Survival in Aggressive Meningiomas | January 7, 2021 | December 31, 2023 |
| NCT06014905 | Recruiting | Phase 1 | Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma | September 1, 2023 | September 30, 2025 |
| NCT06104930 | Recruiting | N/A | Plasma Extracellular Vesicles in Meningioma Patients | November 1, 2023 | February 1, 2026 |
| NCT03095248 | Suspended | Phase 2 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors | May 8, 2017 | June 2025 |
| NCT00003483 | Terminated | Phase 2 | Antineoplaston Therapy in Treating Patients With Meningioma | June 1998 | March 2004 |
| NCT03267836 | Terminated | Phase 1 | Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma | January 10, 2018 | April 6, 2023 |
| NCT02282917 | Terminated | Early Phase 1 | Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma | December 2015 | January 4, 2021 |
| NCT03001349 | Terminated | Early Phase 1 | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | May 16, 2017 | February 5, 2021 |
| NCT00004483 | Unknown status | NF2 Natural History Consortium | January 2002 | ||
| NCT04386642 | Unknown status | Phase 4 | Tranexamic Acid Reduce Blood Loss in Meningioma Resection | September 1, 2021 | September 30, 2022 |
| NCT03631953 | Unknown status | Phase 1 | Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas | September 30, 2019 | September 1, 2022 |
| NCT00985036 | Withdrawn | Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients | September 2009 | January 2012 | |
| NCT03013387 | Withdrawn | Phase 2 | Dosimetry Guided PRRT With 90Y-DOTATOC | January 2017 | October 2019 |
- Disase is a (Disease Ontology)
- DOID:3620
- Cross Reference ID (Disease Ontology)
- GARD:7015
- Cross Reference ID (Disease Ontology)
- ICD10CM:D32.9
- Cross Reference ID (Disease Ontology)
- ICDO:9530/0
- Cross Reference ID (Disease Ontology)
- MESH:D008579
- Cross Reference ID (Disease Ontology)
- NCI:C3230
- Cross Reference ID (Disease Ontology)
- NCI:C6971
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:269643009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0025286
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1334698
- Exact Synonym (Disease Ontology)
- meningeal neoplasm
- Exact Synonym (Disease Ontology)
- meningothelial cell tumor
- Exact Synonym (Disease Ontology)
- neoplasm of the meninges
- Exact Synonym (Disease Ontology)
- primary Meningeal tumor
- HPO alt_id (Human Phenotype Ontology)
- HP:0006754
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002858
- OrphaNumber from OrphaNet (Orphanet)
- 2495
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008579